Timing of peak troponin T and creatine kinase-MB elevations after percutaneous coronary intervention.

STUDY OBJECTIVE The prognostic significance of elevations in creatine kinase-MB and troponin T (cTnT), which have been conventionally measured 6 to 8 h after percutaneous coronary intervention (PCI), has been established. However, the time to peak biomarker appearance in the circulation has not been defined and is the purpose of this pilot study. DESIGN Nonrandomized, nonconsecutive patient cohort. SETTING Clinical practice, Mayo Clinic, Rochester, MN. PATIENTS Cohort (n = 57) undergoing elective PCI. INTERVENTIONS cTnT and creatine kinase (CK)-MB measured at baseline, 2 h, 4 h, 8 h, and > or = 2 h (mean +/- SEM, 18 +/- 5 h) after PCI. MEASUREMENTS AND RESULTS Postprocedure cTnT elevations were detected in 30 of 57 patients (53%). Of these, 4 of 30 patients (13%) had peak cTnT at 4 h (0.80 +/- 0.40 ng/mL), 5 of 30 patients (17%) had peak cTnT at 8 h (1.07 +/- 0.48 ng/mL), and 21 of 30 patients (70%) had peak cTnT at > or = 12 h (0.21 +/- 0.06 ng/mL); 22 of 30 patients received abciximab. Elevations in CK-MB occurred in 14 of 57 patients (25%). Of these, 3 of 14 patients (21%) demonstrated peak CK-MB at 2 h (18.5 +/- 7.9 ng/mL) and the remainder (11 of 14 patients, 79%) during the 12- to 20-h interval (20.2 +/- 4.4 ng/mL); 12 of 14 patients received abciximab. CONCLUSION More cTnT than CK-MB elevations occur after PCI; however, both biomarkers demonstrate a longer time to peak value than anticipated in clinical practice. Early surveillance monitoring (< 12 h) does not detect peak biomarker levels, especially in patients with normal baseline values. If peak levels are to be used to determine prognosis, then longer time intervals should be used for post-PCI surveillance. The timing of peak elevations appears to be influenced by baselines values as well. Early elevations may reflect the conjoint effects of injury associated with the disease process and the intervention itself. These data suggest that a re-evaluation of surveillance monitoring to account for the variability reported and the influence of baseline elevations of biomarkers may improve the prognostic power of the measurements.

[1]  V. Hasselblad,et al.  Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status: The PARAGON-B Troponin T Substudy , 2001, Circulation.

[2]  A. Jaffe,et al.  Paucity of subtle myocardial injury after angioplasty delineated with MB CK. , 1986, Catheterization and Cardiovascular Diagnosis.

[3]  E. Braunwald,et al.  Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. , 2001, JAMA.

[4]  K. Harre,et al.  Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). , 2002, Journal of the American College of Cardiology.

[5]  E. Topol,et al.  Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. , 1996, Circulation.

[6]  S. Vatner,et al.  Effects of coronary artery reperfusion on myocardial infarct size calculated from creatine kinase. , 1978, The Journal of clinical investigation.

[7]  E. Braunwald,et al.  Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. , 2002, Journal of the American College of Cardiology.

[8]  R. Califf,et al.  Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. , 2000, The American journal of cardiology.

[9]  R. Bonow,et al.  Prognostic implication of creatine kinase elevation following elective coronary artery interventions. , 1997, JAMA.

[10]  A. Jaffe,et al.  It's time for a change to a troponin standard. , 2000, Circulation.

[11]  J. Windle,et al.  Significance of cardiac troponin T release after percutaneous transluminal coronary angioplasty. , 1995, The American journal of cardiology.

[12]  P. Fabbro-Péray,et al.  Relation of minor cardiac troponin I elevation to late cardiac events after uncomplicated elective successful percutaneous transluminal coronary angioplasty for angina pectoris. , 1999, The American journal of cardiology.

[13]  R. Califf,et al.  Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Compl , 1997, Journal of the American College of Cardiology.

[14]  E. Topol,et al.  Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. , 1996, American heart journal.

[15]  E. Topol,et al.  Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. , 2001, The New England journal of medicine.

[16]  K. Shyu,et al.  Cardiac troponin T, creatine kinase, and its isoform release after successful percutaneous transluminal coronary angioplasty with or without stenting. , 1998, American heart journal.

[17]  Fred S Apple,et al.  European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. , 2002, American heart journal.

[18]  F. Bedogni,et al.  Troponin T, troponin I and creatine kinase‐MB mass after elective coronary stenting , 1996, Coronary artery disease.

[19]  J. Ravkilde,et al.  Cardiac troponin T and CK-MB mass release after visually successful percutaneous transluminal coronary angioplasty in stable angina pectoris. , 1994, American heart journal.

[20]  W. Gibler,et al.  National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. , 1999, Clinical chemistry.

[21]  J S Alpert,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.

[22]  V. Hasselblad,et al.  Prognostic significance of elevated troponin I after percutaneous coronary intervention. , 2002, Journal of the American College of Cardiology.

[23]  D. Baim,et al.  Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. , 1994, The American journal of cardiology.

[24]  R. Califf,et al.  Minimal myocardial damage during coronary intervention is associated with impaired outcome. , 1999, European heart journal.

[25]  R. Califf,et al.  Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. , 1999, Circulation.

[26]  R. Califf,et al.  Myonecrosis after revascularization procedures. , 1998, Journal of the American College of Cardiology.

[27]  H. Arnesen,et al.  Myocardial damage during percutaneous transluminal coronary angioplasty as evidenced by troponin T measurements. , 1998, European heart journal.

[28]  R. Califf,et al.  Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention , 1999 .

[29]  Ric,et al.  CARDIAC TROPONIN T LEVELS FOR RISK STRATIFICATION IN ACUTE MYOCARDIAL ISCHEMIA , 2000 .